#USA #New York #Wolf Haldenstein #Corcept Therapeutics #CORT

Wolf Haldenstein Encourages Affected Corcept Shareholders to Reach Out

Recently, a securities class action lawsuit was filed against Corcept Therapeutics (NASDAQ: CORT) on behalf of investors who purchased the company's securities between October 31, 2024, and December 30, 2025. The law firm, Wolf Haldenstein Adler Freeman & Herz LLP, is actively seeking to represent shareholders who may have sustained financial losses during this period. Investors interested in participating in this class action have until April 21, 2026, to express their interest and potentially be appointed as lead plaintiffs.

Background on the Allegations

The class action arises from serious allegations against Corcept’s management. The complaint claims that Corcept made false and misleading statements regarding the clinical trials supporting their drug relacorilant, which was being considered for approval by the U.S. Food and Drug Administration (FDA).

Specifically, the lawsuit asserts that the company overhyped the efficacy of relacorilant and misled investors by claiming to have maintained open communication with the FDA, suggesting that the drug was on a clear path towards approval. However, according to the allegations, the FDA had raised significant concerns regarding the evidence supporting the New Drug Application (NDA) and had signaled that the approval was far from guaranteed.

Importance of Timely Action

Affected investors are encouraged to reach out to Wolf Haldenstein for guidance on whether they may qualify to join the lawsuit. The firm is deeply invested in protecting investors' rights and has a long history of handling securities litigation, amassed over 125 years of experience in the field. They emphasize the importance of acting quickly, as the deadline for submitting lead plaintiff applications is approaching.

How to Get Involved

Potential plaintiffs who have suffered losses from Corcept’s stock can contact Wolf Haldenstein via phone at (800) 575-0735 or (212) 545-4774, or they may visit their website for further information. The firm emphasizes that they are dedicated to providing justice for those impacted by misleading corporate practices and is prepared to offer the necessary legal assistance.

Conclusion

As the situation with Corcept Therapeutics unfolds, it is vital for investors who feel they have been wronged to seek legal counsel and consider their options for participation in the class action lawsuit. Wolf Haldenstein's commitment to holding companies accountable for their actions positions them as strong advocates for those seeking reparations for financial losses.

Shareholders are urged to act swiftly and not to miss the opportunity to protect their rights in this ongoing legal matter.